Growth Metrics

Adaptive Biotechnologies (ADPT) Operating Leases (2020 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Operating Leases for 6 consecutive years, with $70.2 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 11.27% to $70.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.2 million through Dec 2025, down 11.27% year-over-year, with the annual reading at $70.2 million for FY2025, 11.27% down from the prior year.
  • Operating Leases hit $70.2 million in Q4 2025 for Adaptive Biotechnologies, down from $72.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $108.0 million in Q3 2021 to a low of $70.2 million in Q4 2025.
  • Historically, Operating Leases has averaged $90.9 million across 5 years, with a median of $93.0 million in 2023.
  • Biggest five-year swings in Operating Leases: surged 160.64% in 2021 and later dropped 12.04% in 2025.
  • Year by year, Operating Leases stood at $106.7 million in 2021, then dropped by 7.42% to $98.8 million in 2022, then dropped by 9.5% to $89.4 million in 2023, then dropped by 11.46% to $79.1 million in 2024, then dropped by 11.27% to $70.2 million in 2025.
  • Business Quant data shows Operating Leases for ADPT at $70.2 million in Q4 2025, $72.4 million in Q3 2025, and $74.4 million in Q2 2025.